MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19.
COVID-19
MBL deficiency
MBL2 genotyping
Prognosis
SARS-CoV-2
Journal
Immunobiology
ISSN: 1878-3279
Titre abrégé: Immunobiology
Pays: Netherlands
ID NLM: 8002742
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
30
05
2021
revised:
29
08
2021
accepted:
20
09
2021
pubmed:
11
10
2021
medline:
15
12
2021
entrez:
10
10
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic represents one of the greatest challenges in modern medicine. The disease is characterized by a variable clinical phenotype, ranging from asymptomatic carriage to severe and/or critical disease, which bears poor prognosis and outcome because of the development of severe acute respiratory distress syndrome (SARS) requiring ICU hospitalization, multi-organ failure and death. Therefore, the determination of risk factors predisposing to disease phenotype is of outmost importance. The aim of our study was to evaluate which predisposing factors, including MBL2 genotyping, affected clinical phenotype in 264 COVID-19 patients. We demonstrated that older age along with underlying comorbidities, primarily obesity, chronic inflammatory disorders and diabetes mellitus, represent the most important risk factors related to hospitalization, the development of pneumonia and SARS. Moreover, we found that the presence of the MBL deficiency-causing B allele (rs1800450) was significantly associated with almost 2-fold increased risk for developing pneumonia and requiring hospitalization, suggesting its usage as a molecular predictor of severe disease in SARS-CoV-2 infected individuals.
Identifiants
pubmed: 34628288
pii: S0171-2985(21)00084-X
doi: 10.1016/j.imbio.2021.152136
pmc: PMC8462051
pii:
doi:
Substances chimiques
MBL2 protein, human
0
Mannose-Binding Lectin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152136Informations de copyright
Copyright © 2021 Elsevier GmbH. All rights reserved.
Références
Int J Infect Dis. 2014 Dec;29:1-6
pubmed: 25312983
Eur J Intern Med. 2021 Jun;88:52-62
pubmed: 33820686
Genes Immun. 2003 Jun;4(4):269-74
pubmed: 12761563
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
PLoS One. 2014 Jun 05;9(6):e98571
pubmed: 24901869
Lancet. 1999 Mar 27;353(9158):1049-53
pubmed: 10199352
J Infect Dis. 2005 Oct 15;192(8):1355-61
pubmed: 16170752
Elife. 2021 Mar 08;10:
pubmed: 33682678
Genet Test Mol Biomarkers. 2014 Sep;18(9):630-5
pubmed: 25019352
Int J Chron Obstruct Pulmon Dis. 2009;4:157-67
pubmed: 19436688
Chest. 2011 Jan;139(1):43-51
pubmed: 20688922
J Infect. 2015 Jul;71(1):101-9
pubmed: 25818534
Diabetes Care. 2021 Jun;44(6):1281-1290
pubmed: 33858854
Mol Cell Biochem. 2021 Aug;476(8):2917-2942
pubmed: 33745077
J Immunol. 1995 Sep 15;155(6):3013-20
pubmed: 7673719
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Cureus. 2021 Feb 18;13(2):e13420
pubmed: 33763316
J Clin Invest. 1993 Apr;91(4):1414-20
pubmed: 7682571
Lancet. 1997 Jan 25;349(9047):236-40
pubmed: 9014910
J Glob Health. 2021 Mar 01;11:10001
pubmed: 33767855
J Thorac Imaging. 2020 Jul;35(4):W97-W101
pubmed: 32235187
Syst Rev. 2021 Mar 20;10(1):80
pubmed: 33743821
Pediatr Allergy Immunol. 2011 Jun;22(4):424-30
pubmed: 21226765
Tissue Antigens. 2005 Oct;66(4):291-6
pubmed: 16185324
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Infect Genet Evol. 2021 Apr;89:104717
pubmed: 33515713
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
J Immunol Res. 2015;2015:478412
pubmed: 25879044
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
Immunobiology. 2007;212(3):201-11
pubmed: 17412287
J Infect Dis. 2005 May 15;191(10):1697-704
pubmed: 15838797
Mol Immunol. 2003 Nov;40(7):423-9
pubmed: 14568388
Medicine (Baltimore). 2021 Mar 26;100(12):e24971
pubmed: 33761654